氯尼甘酯 | 21829-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 氯尼甘酯
• 中文别名: 氯尼塞利；氟尼甘林；氯苄烟酸甘油酯
• 英文名称: NSC335504
• 英文别名: clonixeril；2,3-dihydroxypropyl 2-(3-chloro-2-methylanilino)pyridine-3-carboxylate
• CAS: 21829-22-1
• 化学式: C₁₆H₁₇ClN₂O₄
• 分子量: 336.775
• InChiKey: SWYJYGCPTGKBDS-UHFFFAOYSA-N

物化性质

• 沸点：
  538.7±50.0 °C(Predicted)
• 密度：
  1.384±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  91.7
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  2-(3-Chloro-2-methyl-phenylamino)-nicotinic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 氯尼甘酯
  参考文献：
  名称：

  [EN] STING Modulators, Compositions, and Methods of Use
  [FR] MODULATEURS DE STING, COMPOSITIONS ET MÉTHODES D'UTILISATION

  摘要：

  The present disclosure is directed to compounds of Formula (I), or pharmaceutically acceptable salts thereof and compounds of Formula (II), or pharmaceutically acceptable salts thereof, that modulate stimulator of interferon genes (STING), compositions comprising such compounds, and methods of using same for the treatment of disorders such as cancer and autoimmune disease.

  公开号：

  WO2023034587A1

文献信息

• [EN] PEPTIDE-BASED MULTIPLE-DRUG DELIVERY VEHICLE<br/>[FR] VÉHICULE D'ADMINISTRATION DE MÉDICAMENTS MULTIPLES À BASE DE PEPTIDES
  申请人：ARIEL-UNIVERSITY RES AND DEV COMPANY LTD

  公开号：WO2017068577A1

  公开（公告）日：2017-04-27

  A molecular structure comprising a targeting moiety, a multi-functional peptide platform and a plurality of controllably released bioactive agents attached thereto is provided herein.

  本文提供了一种包括靶向基团、多功能肽平台和附着在其上的多种可控释放的生物活性剂的分子结构。
• [EN] THERANOSTIC CONJUGATES<br/>[FR] CONJUGUÉS THÉRANOSTIQUES
  申请人：ARIEL SCIENT INNOVATIONS LTD

  公开号：WO2021009759A1

  公开（公告）日：2021-01-21

  Provided herein is a drug delivery (DD) system for ratiometric luminescence determination of drug release degree in drug delivery monitoring, which includes a drug, a switchable reporter and non-switchable reporter providing two distinguishable signals for detection; or a single switchable reporter providing two distinguishable signals for detection, and a cleavable linker connecting a drug to a switchable reporter, as well as a method for ratiometric luminescence determination of drug release in a target in vivo or in vitro), which is effected by administering the DD system provided herein that is capable of releasing a drug from the DD system, measuring two luminescent signals provided by the switchable reporter and the non-switchable reporter, or the single switchable reporter, determining the ratio between these two luminescence signals, and determining the drug release degree through the ratio between the two luminescence signals.

  本文提供了一种药物递送（DD）系统，用于药物递送监测中药物释放程度的比例荧光测定，该系统包括一种药物、一种可切换的报告物和一种不可切换的报告物，用于提供两种可区分的信号以进行检测；或者一种单一可切换的报告物，用于提供两种可区分的信号以进行检测，以及一种可切割的连接剂，连接药物和可切换的报告物，以及一种比例荧光测定方法，用于在目标（体内或体外）中测定药物释放，通过给予本文提供的能够从DD系统中释放药物的DD系统，测量可切换的报告物和不可切换的报告物提供的两个发光信号，或者单一可切换的报告物，确定这两个发光信号之间的比例，并通过这两个发光信号之间的比例确定药物释放程度。
• CARBONATES OF FENICOL ANTIBIOTICS
  申请人：Glinka Tomasz W.

  公开号：US20070155799A1

  公开（公告）日：2007-07-05

  Novel fenicol compounds having useful properties as antibiotic prodrugs, are provided, together with methods of making and using these new compounds.

  提供了具有作为抗生素前药有用特性的新颖费诺酮化合物，以及制备和使用这些新化合物的方法。
• USE OF BENZO-HETEROARYL SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN
  申请人：Smith-Swintosky Virginia L.

  公开号：US20070191452A1

  公开（公告）日：2007-08-16

  The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-heteroaryl sulfamide derivatives of formula (I) as herein defined. The present invention is further directed to methods for the treatment of pain comprising co-therapy with analgesic agent(s) and a compound of formula (I) as described herein.

  本发明涉及一种用于治疗疼痛的方法，包括向需要的受试者施用一种或多种新型苯并杂环磺胺衍生物的治疗有效量，其化学式如下所定义。本发明还涉及一种治疗疼痛的方法，包括与镇痛剂联合治疗以及本文描述的化合物的联合治疗。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。